January 13, 2022
BOULDER, Colo. — Treehouse Eyes will be sharing the results from its Clinical Algorithm for Myopia Progression (CAMP) study at the upcoming Global Specialty Lens Symposium.
The CAMP study followed more than 340 children in myopia treatment in a real-world clinical setting, gathering both refractive error and axial length data. The study followed all children examined with at least one year of data in various treatments, including optical and pharmacological interventions, through three years, and showed the effectiveness of the Treehouse Vision System (TVS) clinical protocol. Overall, the results showed that using the Treehouse Vision System led to minimal change (<=0.25D/year) in cycloplegic spherical equivalent refractive error (CSER) in nearly 80% of the children in the study.
“It is very satisfying to be a part of this pioneering study and demonstrate the impact a good clinical protocol can have in reducing myopia progression,” said Kevin Chan, OD, FAAO, Senior Clinical Director for Treehouse Eyes. “Our clinical treatment algorithm demonstrated excellent control of CSER and axial length (AL) as compared to age and ethnicity matched virtual myopic control group data. Custom orthokeratology and soft multifocal contact lenses showed the lowest amount of change over time. The treatment protocol was successful for modifying the treatment for myopic progression in a high-risk group of children and provides a model that can be applied in other practice settings. Results varied significantly, indicating customization of treatments is warranted to optimize results. I look forward to sharing a poster on our findings at the upcoming GSLS.”
“The CAMP study is pivotal to advance our understanding of how different treatments impact myopia progression in a real-world clinical setting,” said Earl Smith, OD, PhD, and one of the authors of the CAMP study. “With a sample size of 342 mostly high-risk children followed for multiple years with refractive error and axial length measurements, this study will help us develop a new protocol to customize treatments for even better results. These children were treated with a variety of methods and some with a combination of atropine and a contact lens, so this is pioneering work to help move us forward as myopia treatment becomes standard of care.”
“I’m proud of the groundbreaking work our team has done to help understand the effectiveness of different treatments to slow the progression of childhood myopia,” said Matt Oerding, CEO of Treehouse Eyes. “We’ve demonstrated fantastic real-world clinical results in a large group of children with our existing Treehouse Vision System clinical protocol. I’m excited to use the results of the CAMP study to make our current proprietary protocol for clinical decision making even easier and achieve even better results with a customized treatment approach. As the leading providers of myopia treatment, we have an obligation to continue to lead from the front to help more children get effective treatment for their myopia.”